All I can say is most of us have no idea how much of a game changer this is. On Oct. 3, 2012 NLNK announced the launching of an open-label, randomized, multi-institutional adaptive design Phase2B/3 study to evaluate efficacy of its tergenpumatucel-L (HyperAcute® Lung) product candidate in patients with progressive or relapsed Stage-IIIB/IV non-small cell lung cancer (NSCLC).
FYI the 5 year survival of Stage IIIB patients is 7% and Stage IV patients 2%. Survival rates havn't moved much over the last 50 years.
Their Phase II study showed 21.9 vs. 7 months survival for patients that had a strong enough immune system to generate IFN-gamma responses.
Do the math at 20M, 22, 25 M shares outstanding whatever, it matters not.
We should see initial results of the phase 2b trial at the end of next year and I believe the pancreatic cancer trial will have been unblinded well before that. 2013 will be NewLink's coming out party.